ARRY has been going down for too long since they they withdrawn their FDA application for its skin cancer drug binimetinib after poor P3 results. Stock seems oversold atm. Yesterday's results were quite positive. May have a short squeeze.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.